In the statement, obviously a number of specific regulatory commitments were laid out in terms of priorities for officials and for the government to get through. Timelines will vary from item to item. You raised the example of the plants with novel traits. We are engaging with the sector right now through CFIA, the AAFC and indeed Health Canada to talk with the sector about ways we can simplify and clarify the approval process. That's ongoing. The precise timing will depend on the nature of the discussions, but these discussions are ongoing.
For some of the other regulatory items—Jaspinder could probably talk about some of the CFIA stuff—it will have to go through normal processes to the extent that there are changes, gazetting processes, and so on.